Results 111 to 120 of about 46,564 (215)

Challenges in the future of cancer screening

International Journal of Cancer, Volume 158, Issue 8, Page 2013-2022, 15 April 2026.
Abstract The purpose of cancer screening is to reduce mortality, and ideally incidence, from the cancer screened for. Until recently, cancer screening has been offered to all persons in pre‐defined sex‐ and age‐groups. The exception is lung screening which is targeted to high‐risk individuals.
Elsebeth Lynge, Berit Andersen, Stig E. Bojesen, Lone Kjeld Petersen, Mickael Bech, Martin Bøgsted, Mie Seest Dam, Søren Egstrand, Anne Mette Fløe Hvass, Camilla J. Kobylecki, Kristina Lång, Mads Nielsen, Giorgi Paolo Rossi, Michael Stenger, Ilse Vejborg, Future of Cancer Screening Working Group, Vibe Munk Bertelsen, Janne Bigaard, Karen Omann Binderup, Lennart Friis‐Hansen, Stine Bisgaard Greve, Jessica Xin Hjaltelin, Rikke Hedegaard Jensen, Gitte Jessing, Pia Kirkegaard, Mette Hartmann Nonboe, Tina Bech Olesen, Katrine Stolberg, Signe Bülow Therkildsen, Mette Kielsholm Thomsen   +29 more
wiley   +1 more source

BRCA2 Gene [PDF]

, 2020
openaire   +1 more source

Behold BRCA2! [PDF]

Nature Genetics, 1996
openaire   +1 more source

BRCA2-repair [PDF]

Genome Biology, 2001
openaire   +1 more source

Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition. [PDF]

PLoS One
Chapman IG, Wu X, Veuger S, Jowsey PA.
europepmc   +1 more source

BRCA2 interacting proteins [PDF]

Breast Cancer Research, 2000
Vidarsson, H, Mikaelsdottir, E, Eyfjörd, JE, Ögmundsdóttir, H, Rafnar, T, Valgeirsdóttir, S   +5 more
openaire   +1 more source

BRCA1 and BRCA2 pathogenic variants increase the risk of four less common cancer types. [PDF]

ESMO Open
Sasagawa H, Endo M, Iwasaki Y, Usui Y, Koyanagi YN, Innella G, Hadler J, Parsons MT, Numakura K, Kamatani Y, Murakami Y, Matsuo K, Matsuda K, Spurdle AB, Habuchi T, Momozawa Y.   +15 more
europepmc   +1 more source

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. [PDF]

Clin Cancer Res
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM.   +38 more
europepmc   +1 more source

BRCA2 Syndrome [PDF]

, 2020
openaire   +1 more source

From mutation to treatment: The dual role of BRCA1 and BRCA2 in gynecological malignancy development and management a systematic review. [PDF]

Biochem Biophys Rep
Georgy DM, Sedeek HN, Abaza NE, Eldeeb SEK, Khamis SM, Elgamil MR, Magar RW.   +6 more
europepmc   +1 more source